Meprednisone
FDA-approved product (tablet, oral), marketed as Betapar.
- Registered studies
- 2
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLNo approved indication recorded
ChEMBL records no approved indication for Meprednisone. Its therapeutic class is shown instead.
- WHO therapeutic group
- Glucocorticoids
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA54.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli31.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae24.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis24.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
2registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Meprednisone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Cabozantinib S-MalateExisting use: Cancer, Clear cell renal carcinoma, Hepatocellular carcinoma and 7 more64.4% AI-predicted activityagainst M. tuberculosis45 registered studies
- Fondaparinux SodiumExisting use: Deep vein thrombosis, Intermediate coronary syndrome, Myocardial infarction and 3 more64.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- MidazolamExisting use: Amnesia, Epilepsy, Seizure and 1 more64.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Moricizine HydrochlorideExisting use: Cardiac arrhythmia64.4% AI-predicted activityagainst M. tuberculosis3 registered studies
- Prasugrel HydrochlorideExisting use: Acute coronary syndrome, Hemorrhage, Intermediate coronary syndrome and 1 more64.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Vinorelbine TartrateExisting use: Cancer, Neoplasm64.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Dolutegravir SodiumExisting use: HIV infection, HIV-1 infection64.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- PirtobrutinibExisting use: Mantle cell lymphoma, Neoplasm64.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- EncorafenibExisting use: Cancer, Colorectal adenocarcinoma, Colorectal cancer and 5 more64.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- EfavirenzExisting use: HIV infection, HIV-1 infection, Immunodeficiency disease and 2 more63.9% AI-predicted activityagainst M. tuberculosis50+ registered studies
- PosaconazoleExisting use: Aspergillosis, Candidiasis, Coccidioidomycosis and 2 more63.9% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Acetophenazine MaleateExisting use: Psychosis63.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
Registered studies
A registration describes a study; it does not establish a positive result.
Methylprednisolone Combined Electric-acupuncture on Cognitive Function
NCT02535039 · start 2015-10
Registered record
- Registry ID
- NCT02535039
- Conditions
- Postoperative Complication; Cognitive Retention Disorder
- Interventions
- Methylprednisolone; Physiological saline
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Unknown
- Start
- 2015-10
- Completion
- 2016-12
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostoperative Complication; Cognitive Retention DisorderInterventionMethylprednisolone; Physiological salinePhasePhase 1 / Phase 2Registry statusUnknownEvaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
NCT00623766 · start 2008-07
Registered record
- Registry ID
- NCT00623766
- Conditions
- Melanoma
- Interventions
- Ipilimumab; Corticosteroid: Betamethasone; Corticosteroid: Dexamethasone; Corticosteroid: Fludrocortisone; Corticosteroid: Hydrocortisone; Corticosteroid: Meprednisone; Corticosteroid: Methylprednisolone; Corticosteroid: Prednisolone; Corticosteroid: Prednisone; Corticosteroid: Triamcinolone
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2008-07
- Completion
- 2012-10
- Enrolment
- 99
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMelanomaInterventionIpilimumab; Corticosteroid: Betamethasone; Corticosteroid: Dexamethasone; Corticosteroid: Fludrocortisone +6 morePhasePhase 2Registry statusCompleted